Relia Tech/Rat Anti-Mouse CCL-9/100 µg/103-M338
市场价：
¥5500.00
美元价：
3300.00
产品分类：
单克隆抗体
公司分类：
monoclonal_antibody
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Cat-Nr. | 103-M338 |
| Size | 100 µg |
| Price | 275 € |
| Category | Monoclonal Antibody |
| Clone Nr. | (#28B3) |
| Isotype | IgG2 |
| Species Reactivity | Mouse |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml. |
| Stability and Storage | Lyophilized samples are stable for 2 years from date of receipt when stored at -70°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity. |
| Preparation | This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a rat) immunized with mouse recombinant protein of CCL-9. |
| Antigen | recombinant mouse CCL-9 |
| Application | WB, N |
| Synonyms | Ccl9; CCF18; MRP-2; Scya9; Scya10 |
| Description | Mouse CCL9/10 (also named MIP1γ and MRP2) is an 11 kDa, secreted, monomeric polypeptide that belongs to the β (or CC) intercrine family of chemokines. Based on its activity and amino acid (aa) sequence, it is further classified as a member of the NC6 or six cysteinecontaining CC subfamily of chemokines. This subfamily contains four Nterminally extended chemokines, two human (CCL15 and CCL23) and two mouse (CCL9 and CCL10). Within this subfamily, there are no humanto rodent interspecies orthologs. Mouse CCL9/10 is synthesized as a 122 aa precursor that contains a 21 aa signal sequence and a 101 aa mature region with six cysteines. As noted, the mature region has an expanded Nterminus relative to other CC family members, and it forms a third intrachain disulfide bond with its two extra cysteines. Mouse CCL9/10 is 75% aa identical to rat CCL9/10. Chemokines are known to undergo proteolytic processing to generate multiple isoforms. NC6 chemokines are usually only marginally active at fulllength, but are converted to highly active forms upon Nterminal truncation. Mature CCL9, in the presence of inflammatory fluids, is naturally truncated by 28, 29 or 30 aa at the Nterminus, generating a highly active, 8 kDa, 71 73 aa CCR1 ligand. In contrast, other CCR1 ligands, CCL3/MIP1α and CCL5/RANTES, lose their potency when proteolytically processed. CCL9/10 is constitutively secreted, and circulates as a fulllength molecule. Any onset of inflammation with subsequent enzyme release may act on local NC6 chemokines, generating early, potent leukocyte chemoattractants. |
| Uniprot ID | P51670 |
| Protein RefSeq | NP_035468.1 |
| mRNA RefSeq | NM_011338.2 |
品牌介绍
Receptor Ligand Technologies GmbH 公司（RELIA Tech ）位于德国不伦瑞克，是一家后基因组生物技术公司，该公司运用独特的技术专注于受体和配体的发现与研究，从而使商业化，产品广泛使用于科学研究，实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子，生长因子，重组蛋白产品一致内毒素检测项目，且内毒素水平非常低。 受体配体技术有限公司（RELIATech）是一家后基因组生物技术公司，致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化，用于研究，诊断和临床领域。该公司位于德国不伦瑞克，由以下公司成立于2000年10月： 阿夫纳·亚永教授以色列魏兹曼科学研究所（WIS） 赫伯特·韦奇博士德国生物技术德国研究中心（GBF） Bernhard Barleon博士德国肿瘤生物学诊所（KTB） 创始人是从事细胞生长因子相互作用，酪氨酸激酶及其信号传导途径（涉及组织重塑，体内平衡和疾病）领域的细胞和分子生物学家，工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成，肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白，连同其跨膜/“可溶性受体”和相关的激酶，在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化，组织重塑和体内平衡，并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现，以及对它们功能的阐明，无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品，用于基础研究，药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们
